Form 4: United Therapeutics CEO Exercises, Sells Stock

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock totaling 8,000 shares across two dates in late October and early November 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving the exercise of stock options and subsequent sale of common stock.
• On October 31, 2025, Rothblatt exercised options for 4,000 shares at an exercise price of $120.26 per share.
• Immediately following the exercise on October 31, 2025, 4,000 shares were sold at weighted average prices ranging from $447.826 to $451.4864 per share.
• On November 3, 2025, Rothblatt exercised options for another 4,000 shares at an exercise price of $120.26 per share.
• Immediately following the exercise on November 3, 2025, 4,000 shares were sold at weighted average prices ranging from $433.7769 to $443.01 per share.
• All transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• Following these transactions, Rothblatt directly holds 130 shares of Common Stock.
• Indirect beneficial ownership includes 166 shares by spouse, 324,518 shares by Trust (7), 258,117 shares by Trust (8), 45,596 shares by Trust (9), and 15,962 shares by Trust (10).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The transactions are routine, pre-planned insider sales for liquidity/diversification, not indicative of new negative information. The significant profit from option exercise is a positive for the insider.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, non-public information.
• The exercise price of $120.26 is significantly lower than the sale prices (ranging from $433.7769 to $451.4864), demonstrating substantial unrealized gains on the options.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors, although these are routine option exercises and sales for liquidity/diversification.

Future Outlook

The pre-arranged 10b5-1 trading plan is scheduled to continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026, or December 31, 2025.

Related Party Transactions

• The reporting person's beneficial ownership includes shares held indirectly through various family trusts, some of which involve the reporting person's spouse or immediate family members as beneficiaries or trustees.

Stakeholder Impact

• Shareholders: The transactions represent routine, pre-planned insider selling, which typically has minimal impact on shareholder sentiment unless the scale is unusually large or unplanned.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continuation of the 10b5-1 trading plan until its specified end date or option exhaustion.

Key Dates

Recommendation

This Form 4 filing details pre-planned insider transactions (exercise of options and sale of shares) by the CEO. Such routine transactions, executed under a 10b5-1 plan, are generally not considered a significant indicator for a 'buy' or 'sell' recommendation. They primarily reflect personal financial planning rather than a change in the company's fundamental outlook. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an existing investment thesis.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Equity Sales